Interaction between naltrexone and oral THC in heavy marijuana smokers.
Margaret Haney, Adam Bisaga, Richard W Foltin
Psychopharmacology February 2003 DOI: 10.1007/s00213-002-1279-8 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Controlled human laboratory study (three sub-studies) Peer reviewed |
|---|---|
| Sample size | 23 |
| Population | Heavy marijuana smokers |
| Interventions | Naltrexone THC Methadone |
| Dose | naltrexone 0, 50 mg; THC 0, 15, 30 mg; methadone 5, 10 mg |
| Measures | Good Drug Effect, Capsule Liking, drug choice test |
| Topics | Cannabis |
| Key points | Naltrexone pretreatment significantly increased many positive subjective effects of 30 mg oral THC, such as ratings of Good Drug Effect and Capsule Liking, and tended to increase THC's reinforcing effects in a drug choice test, while not altering plasma THC levels. The authors argue that in heavy marijuana smokers, oral THC's effects are enhanced rather than antagonized by opioid receptor blockade, contrary to animal studies suggesting opioid antagonists block cannabinoid reinforcement. |
Abstract
Studies in non-human animals suggest that opioid antagonists block the reinforcing effects of cannabinoids. The present studies in humans investigated how naltrexone modulates (1) the subjective and physiological effects of oral THC in comparison to methadone, (2) the reinforcing effects of oral THC, and (3) plasma levels of oral THC. In study 1, marijuana smokers (n=9) received naltrexone (0, 50 mg) followed 30 min later by THC (0, 15, 30 mg) or methadone (5, 10 mg). Subjective effects, task performance, pupillary diameter, and cardiovascular parameters were measured repeatedly. In study 2a, marijuana smokers (n=23) were randomly assigned to one THC dose condition (0, 15 or 30 mg). One set of color-coded capsules containing THC and active naltrexone (50 mg) was given in one session, while another set of color-coded capsules containing THC and placebo naltrexone was given in another session. In the final three sessions, participants chose which color capsules they would receive. In study 2b, a subset of participants from study 2a (n=7) received naltrexone (0, 50 mg) 30 min prior to oral THC (30 mg) administration, and blood was drawn repeatedly. Pretreatment with naltrexone significantly increased many of the "positive" subjective effects of oral THC (30 mg) e.g. ratings of Good Drug Effect and Capsule Liking. Naltrexone tended to increase the reinforcing effects of oral THC (30 mg), as indicated by performance in a drug choice test. Naltrexone did not alter plasma THC levels. These studies demonstrate that naltrexone increases the subjective effects of oral THC. Thus, oral THC's effects are enhanced rather than antagonized by opioid receptor blockade in heavy marijuana smokers.
Comparable studies
Other experimental studies on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Smoked Cannabis' Psychomotor and Neurocognitive Effects in Occasional and Frequent Smokers Occasional (<2x/week) and frequent (≥4x/week) cannabis smokers | 2015 | Controlled within-subjects study | n = 25 |
| Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity Healthy volunteers experienced with cannabis but not regular users | 2019 | Within-subjects experimental design | n = 17 |
| Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects? Young cannabis users | 2018 | Observational study (naturalistic, within-subject counterbalanced design) | n = 410 |
| Cannabis Essential Oil: A Preliminary Study for the Evaluation of the Brain Effects Healthy volunteers | 2018 | Experimental study | n = 5 |
| Coming off cannabis: a cognitive and magnetic resonance imaging study in patients with multiple sclerosis Patients with multiple sclerosis who began using cannabis after disease onset, used it... | 2019 | Quasi-experimental study with odd-even allocation | n = 40 |
Citations in the library
Cited by 8
- PHARMACOLOGY OF NOVAL CANNABINOIDS International Journal of Pharmacy and Pharmaceutical Sciences December 9, 2019
- Use of a Novel EEG-Based Objective Test, the Cognalyzer®, in Quantifying the Strength and Determining the Action Time of Cannabis Psychoactive Effects and Factors that May Influence Them Within an Observational Study Framework. Neurology and therapy March 1, 2022
- Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users? Neurotoxicity Research November 1, 2016
- Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. The International Journal of Neuropsychopharmacology October 2012
- The safety of modafinil in combination with oral ∆9-tetrahydrocannabinol in humans. Pharmacology, Biochemistry, and Behavior March 2011
and 3 more in the library
Cites 2
- Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology July 1, 2001
- Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science January 15, 1999